Notably, the results of bioinformatics analyses indicate that GPX4 and ACSL4 are positively and negatively correlated with the sensitivity of sorafenib in RCC, respectively (Fig. 3C). This evidence concerns the gene ACSL4 and renal cell carcinoma.